Selected research
Market Structure
Global mRNA Vaccine Drugs Development Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global mRNA Vaccine Drugs Development Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of mRNA Vaccine Drugs Development Services include ReciBioPharm, Merck, Samsung Biologics, Thermo Fisher Scientific, Lonza, Ricoh Group, Aldevron, Wuxi Biologics and Genscript Probio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global mRNA Vaccine Drugs Development Services market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of mRNA Vaccine Drugs Development Services and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents mRNA Vaccine Drugs Development Services revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the mRNA Vaccine Drugs Development Services market size, projected growth trends, production technologies, key applications, and end-use industries.
mRNA Vaccine Drugs Development Services Segment by Company
ReciBioPharm
Merck
Samsung Biologics
Thermo Fisher Scientific
Lonza
Ricoh Group
Aldevron
Wuxi Biologics
Genscript Probio
Novoprotein
Porton Advanced Solutions
Precision NanoSystems
mRNA Vaccine Drugs Development Services Segment by Type
mRNA Process Development Services
mRNA Synthesis Services
mRNA Drug Substance Purification Services
Others
mRNA Vaccine Drugs Development Services Segment by Application
Non-Replicating mRNA Vaccine Drugs
Self-Amplifying mRNA Vaccine Drugs
mRNA Vaccine Drugs Development Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccine Drugs Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccine Drugs Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccine Drugs Development Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of mRNA Vaccine Drugs Development Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Vaccine Drugs Development Services industry.
Chapter 3: Detailed analysis of mRNA Vaccine Drugs Development Services companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Vaccine Drugs Development Servicesrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- mRNA Process Development Services
- mRNA Synthesis Services
- mRNA Drug Substance Purification Services
- Others
Applications
- Non-Replicating mRNA Vaccine Drugs
- Self-Amplifying mRNA Vaccine Drugs
Companies covered
- ReciBioPharm
- Merck
- Samsung Biologics
- Thermo Fisher Scientific
- Lonza
- Ricoh Group
- Aldevron
- Wuxi Biologics
- Genscript Probio
- Novoprotein
- Porton Advanced Solutions
- Precision NanoSystems
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global mRNA Vaccine Drugs Development Services Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 mRNA Process Development Services
- 1.2.3 mRNA Synthesis Services
- 1.2.4 mRNA Drug Substance Purification Services
- 1.2.5 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global mRNA Vaccine Drugs Development Services Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Non-Replicating mRNA Vaccine Drugs
- 1.3.3 Self-Amplifying mRNA Vaccine Drugs
- 1.4 Global Market Growth Prospects
- 1.5 Global mRNA Vaccine Drugs Development Services Growth Trends by Region
- 1.5.1 Global mRNA Vaccine Drugs Development Services Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 mRNA Vaccine Drugs Development Services Market Size by Region (2021-2026)
- 1.5.3 mRNA Vaccine Drugs Development Services Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global mRNA Vaccine Drugs Development Services Market Dynamics
- 2.1 mRNA Vaccine Drugs Development Services Industry Trends
- 2.2 mRNA Vaccine Drugs Development Services Industry Drivers
- 2.3 mRNA Vaccine Drugs Development Services Industry Opportunities and Challenges
- 2.4 mRNA Vaccine Drugs Development Services Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global mRNA Vaccine Drugs Development Services Revenue by Company (2021-2026)
- 3.2 Global mRNA Vaccine Drugs Development Services Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global mRNA Vaccine Drugs Development Services Key Company Head office and Area Served
- 3.4 Global mRNA Vaccine Drugs Development Services Company, Product Type & Application
- 3.5 Global mRNA Vaccine Drugs Development Services Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global mRNA Vaccine Drugs Development Services Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 mRNA Vaccine Drugs Development Services Players Market Share by Revenue in 2025
- 3.6.3 2025 mRNA Vaccine Drugs Development Services Tier 1, Tier 2, and Tier 3
4 mRNA Vaccine Drugs Development Services Market by Type
- 4.1 Global mRNA Vaccine Drugs Development Services Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global mRNA Vaccine Drugs Development Services Market Size by Type (2021-2032)
- 4.3 Global mRNA Vaccine Drugs Development Services Market Size Share by Type (2021-2032)
5 mRNA Vaccine Drugs Development Services Market by Application
- 5.1 Global mRNA Vaccine Drugs Development Services Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global mRNA Vaccine Drugs Development Services Market Size by Application (2021-2032)
- 5.3 Global mRNA Vaccine Drugs Development Services Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 ReciBioPharm
- 6.1.1 ReciBioPharm Company Information
- 6.1.2 ReciBioPharm Business Overview
- 6.1.3 ReciBioPharm mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 ReciBioPharm mRNA Vaccine Drugs Development Services Product Portfolio
- 6.1.5 ReciBioPharm Recent Developments
- 6.2 Merck
- 6.2.1 Merck Company Information
- 6.2.2 Merck Business Overview
- 6.2.3 Merck mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Merck mRNA Vaccine Drugs Development Services Product Portfolio
- 6.2.5 Merck Recent Developments
- 6.3 Samsung Biologics
- 6.3.1 Samsung Biologics Company Information
- 6.3.2 Samsung Biologics Business Overview
- 6.3.3 Samsung Biologics mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Samsung Biologics mRNA Vaccine Drugs Development Services Product Portfolio
- 6.3.5 Samsung Biologics Recent Developments
- 6.4 Thermo Fisher Scientific
- 6.4.1 Thermo Fisher Scientific Company Information
- 6.4.2 Thermo Fisher Scientific Business Overview
- 6.4.3 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Product Portfolio
- 6.4.5 Thermo Fisher Scientific Recent Developments
- 6.5 Lonza
- 6.5.1 Lonza Company Information
- 6.5.2 Lonza Business Overview
- 6.5.3 Lonza mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Lonza mRNA Vaccine Drugs Development Services Product Portfolio
- 6.5.5 Lonza Recent Developments
- 6.6 Ricoh Group
- 6.6.1 Ricoh Group Company Information
- 6.6.2 Ricoh Group Business Overview
- 6.6.3 Ricoh Group mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Ricoh Group mRNA Vaccine Drugs Development Services Product Portfolio
- 6.6.5 Ricoh Group Recent Developments
- 6.7 Aldevron
- 6.7.1 Aldevron Company Information
- 6.7.2 Aldevron Business Overview
- 6.7.3 Aldevron mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Aldevron mRNA Vaccine Drugs Development Services Product Portfolio
- 6.7.5 Aldevron Recent Developments
- 6.8 Wuxi Biologics
- 6.8.1 Wuxi Biologics Company Information
- 6.8.2 Wuxi Biologics Business Overview
- 6.8.3 Wuxi Biologics mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Wuxi Biologics mRNA Vaccine Drugs Development Services Product Portfolio
- 6.8.5 Wuxi Biologics Recent Developments
- 6.9 Genscript Probio
- 6.9.1 Genscript Probio Company Information
- 6.9.2 Genscript Probio Business Overview
- 6.9.3 Genscript Probio mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Genscript Probio mRNA Vaccine Drugs Development Services Product Portfolio
- 6.9.5 Genscript Probio Recent Developments
- 6.10 Novoprotein
- 6.10.1 Novoprotein Company Information
- 6.10.2 Novoprotein Business Overview
- 6.10.3 Novoprotein mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Novoprotein mRNA Vaccine Drugs Development Services Product Portfolio
- 6.10.5 Novoprotein Recent Developments
- 6.11 Porton Advanced Solutions
- 6.11.1 Porton Advanced Solutions Company Information
- 6.11.2 Porton Advanced Solutions Business Overview
- 6.11.3 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Product Portfolio
- 6.11.5 Porton Advanced Solutions Recent Developments
- 6.12 Precision NanoSystems
- 6.12.1 Precision NanoSystems Company Information
- 6.12.2 Precision NanoSystems Business Overview
- 6.12.3 Precision NanoSystems mRNA Vaccine Drugs Development Services Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Precision NanoSystems mRNA Vaccine Drugs Development Services Product Portfolio
- 6.12.5 Precision NanoSystems Recent Developments
7 North America
- 7.1 North America mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 7.2 North America mRNA Vaccine Drugs Development Services Market Size by Type
- 7.2.1 North America mRNA Vaccine Drugs Development Services Market Size by Type (2021-2026)
- 7.2.2 North America mRNA Vaccine Drugs Development Services Market Size by Type (2027-2032)
- 7.2.3 North America mRNA Vaccine Drugs Development Services Market Share by Type (2021-2032)
- 7.3 North America mRNA Vaccine Drugs Development Services Market Size by Application
- 7.3.1 North America mRNA Vaccine Drugs Development Services Market Size by Application (2021-2026)
- 7.3.2 North America mRNA Vaccine Drugs Development Services Market Size by Application (2027-2032)
- 7.3.3 North America mRNA Vaccine Drugs Development Services Market Share by Application (2021-2032)
- 7.4 North America mRNA Vaccine Drugs Development Services Market Size by Country
- 7.4.1 North America mRNA Vaccine Drugs Development Services Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 7.4.3 North America mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 7.4.4 North America mRNA Vaccine Drugs Development Services Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 8.2 Europe mRNA Vaccine Drugs Development Services Market Size by Type
- 8.2.1 Europe mRNA Vaccine Drugs Development Services Market Size by Type (2021-2026)
- 8.2.2 Europe mRNA Vaccine Drugs Development Services Market Size by Type (2027-2032)
- 8.2.3 Europe mRNA Vaccine Drugs Development Services Market Share by Type (2021-2032)
- 8.3 Europe mRNA Vaccine Drugs Development Services Market Size by Application
- 8.3.1 Europe mRNA Vaccine Drugs Development Services Market Size by Application (2021-2026)
- 8.3.2 Europe mRNA Vaccine Drugs Development Services Market Size by Application (2027-2032)
- 8.3.3 Europe mRNA Vaccine Drugs Development Services Market Share by Application (2021-2032)
- 8.4 Europe mRNA Vaccine Drugs Development Services Market Size by Country
- 8.4.1 Europe mRNA Vaccine Drugs Development Services Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 8.4.3 Europe mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 8.4.4 Europe mRNA Vaccine Drugs Development Services Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 9.2 China mRNA Vaccine Drugs Development Services Market Size by Type
- 9.2.1 China mRNA Vaccine Drugs Development Services Market Size by Type (2021-2026)
- 9.2.2 China mRNA Vaccine Drugs Development Services Market Size by Type (2027-2032)
- 9.2.3 China mRNA Vaccine Drugs Development Services Market Share by Type (2021-2032)
- 9.3 China mRNA Vaccine Drugs Development Services Market Size by Application
- 9.3.1 China mRNA Vaccine Drugs Development Services Market Size by Application (2021-2026)
- 9.3.2 China mRNA Vaccine Drugs Development Services Market Size by Application (2027-2032)
- 9.3.3 China mRNA Vaccine Drugs Development Services Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 10.2 Asia mRNA Vaccine Drugs Development Services Market Size by Type
- 10.2.1 Asia mRNA Vaccine Drugs Development Services Market Size by Type (2021-2026)
- 10.2.2 Asia mRNA Vaccine Drugs Development Services Market Size by Type (2027-2032)
- 10.2.3 Asia mRNA Vaccine Drugs Development Services Market Share by Type (2021-2032)
- 10.3 Asia mRNA Vaccine Drugs Development Services Market Size by Application
- 10.3.1 Asia mRNA Vaccine Drugs Development Services Market Size by Application (2021-2026)
- 10.3.2 Asia mRNA Vaccine Drugs Development Services Market Size by Application (2027-2032)
- 10.3.3 Asia mRNA Vaccine Drugs Development Services Market Share by Application (2021-2032)
- 10.4 Asia mRNA Vaccine Drugs Development Services Market Size by Country
- 10.4.1 Asia mRNA Vaccine Drugs Development Services Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 10.4.3 Asia mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 10.4.4 Asia mRNA Vaccine Drugs Development Services Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size (2021-2032)
- 11.2 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Type
- 11.2.1 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Application
- 11.3.1 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Country
- 11.4.1 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa mRNA Vaccine Drugs Development Services Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst